Latest Insider Transactions at Gossamer Bio, Inc. (GOSS)
This section provides a real-time view of insider transactions for Gossamer Bio, Inc. (GOSS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Gossamer Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Gossamer Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,908
-0.96%
|
$0
$0.66 P/Share
|
|
Jun 21
2024
|
Faheem Hasnain President & CEO |
BUY
Open market or private purchase
|
Indirect |
372,000
+6.44%
|
$0
$0.67 P/Share
|
|
Jun 18
2024
|
Bryan Giraudo COO/CFO |
BUY
Open market or private purchase
|
Indirect |
100,000
+17.24%
|
$0
$0.59 P/Share
|
|
Jun 17
2024
|
Robert Paul Smith Jr Chief Commercial Officer |
BUY
Open market or private purchase
|
Indirect |
25,000
+50.0%
|
$0
$0.6 P/Share
|
|
Mar 27
2024
|
Waage Christian EVP, Tech Ops and Admin |
SELL
Open market or private sale
|
Direct |
6,430
-1.09%
|
$6,430
$1.16 P/Share
|
|
Mar 27
2024
|
Bryan Giraudo COO/CFO |
SELL
Open market or private sale
|
Direct |
6,430
-6.48%
|
$6,430
$1.16 P/Share
|
|
Mar 27
2024
|
Faheem Hasnain President & CEO |
SELL
Open market or private sale
|
Direct |
23,172
-16.15%
|
$23,172
$1.16 P/Share
|
|
Mar 18
2024
|
Caryn Peterson EVP, Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
4,018
-7.46%
|
$4,018
$1.33 P/Share
|
|
Mar 18
2024
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,018
-1.98%
|
$4,018
$1.33 P/Share
|
|
Nov 15
2023
|
Sandra Milligan Director |
BUY
Open market or private purchase
|
Indirect |
32,000
+50.0%
|
$0
$0.79 P/Share
|
|
Nov 13
2023
|
Bryan Giraudo COO/CFO |
BUY
Open market or private purchase
|
Indirect |
200,000
+34.48%
|
$0
$0.56 P/Share
|
|
Jul 24
2023
|
Waage Christian EVP, Tech Ops and Admin |
BUY
Grant, award, or other acquisition
|
Indirect |
13,504
+22.74%
|
$13,504
$1.82 P/Share
|
|
Jul 24
2023
|
Faheem Hasnain President & CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
540,176
+9.69%
|
$540,176
$1.82 P/Share
|
|
Jul 24
2023
|
Bryan Giraudo COO/CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
54,020
+23.08%
|
$54,020
$1.82 P/Share
|
|
Jun 22
2023
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,814
-0.91%
|
$1,814
$1.29 P/Share
|
|
Apr 04
2023
|
Bryan Giraudo COO/CFO |
BUY
Open market or private purchase
|
Indirect |
55,000
+30.39%
|
$55,000
$1.02 P/Share
|
|
Mar 22
2023
|
Faheem Hasnain President & CEO |
BUY
Open market or private purchase
|
Indirect |
440,500
+8.92%
|
$440,500
$1.14 P/Share
|
|
Mar 21
2023
|
Faheem Hasnain President & CEO |
BUY
Open market or private purchase
|
Indirect |
269,389
+6.23%
|
$269,389
$1.2 P/Share
|
|
Mar 20
2023
|
Faheem Hasnain President & CEO |
BUY
Open market or private purchase
|
Indirect |
168,683
+4.27%
|
$168,683
$1.03 P/Share
|
|
Mar 20
2023
|
Bryan Giraudo COO/CFO |
BUY
Open market or private purchase
|
Indirect |
50,000
+41.33%
|
$0
$0.97 P/Share
|
|
Mar 20
2023
|
Waage Christian EVP, Tech Ops and Admin |
BUY
Open market or private purchase
|
Indirect |
18,500
+36.35%
|
$18,500
$1.2 P/Share
|
|
Mar 16
2023
|
Caryn Peterson EVP, Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
7,564
-12.32%
|
$7,564
$1.1 P/Share
|
|
Mar 16
2023
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,563
-3.65%
|
$7,563
$1.1 P/Share
|
|
Mar 16
2023
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,029
-7.33%
|
$6,029
$1.1 P/Share
|
|
Oct 24
2022
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,757
-2.26%
|
$57,084
$12.07 P/Share
|
|
Oct 24
2022
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,876
-5.59%
|
$58,512
$12.07 P/Share
|
|
Oct 24
2022
|
Caryn Peterson EVP, Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
4,757
-7.19%
|
$57,084
$12.07 P/Share
|
|
Jul 15
2022
|
Faheem Hasnain President & CEO |
BUY
Open market or private purchase
|
Indirect |
138,696
+3.69%
|
$970,872
$7.21 P/Share
|
|
Jul 15
2022
|
Bryan Giraudo COO/CFO |
BUY
Open market or private purchase
|
Indirect |
13,869
+39.79%
|
$97,083
$7.21 P/Share
|
|
Jul 15
2022
|
Waage Christian EVP, Tech Ops and Admin |
BUY
Open market or private purchase
|
Indirect |
6,934
+33.3%
|
$48,538
$7.21 P/Share
|
|
Jul 15
2022
|
Laura Carter Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
6,934
+7.37%
|
$48,538
$7.21 P/Share
|
|
Jul 01
2022
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,808
-9.89%
|
$70,464
$8.25 P/Share
|
|
Jun 22
2022
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,778
-0.84%
|
$10,668
$6.88 P/Share
|
|
May 04
2022
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,262
-1.4%
|
$8,834
$7.2 P/Share
|
|
Mar 23
2022
|
Bryan Giraudo COO/CFO |
SELL
Open market or private sale
|
Direct |
10,722
-9.76%
|
$85,776
$8.91 P/Share
|
|
Mar 23
2022
|
Faheem Hasnain President & CEO |
SELL
Open market or private sale
|
Direct |
19,035
-11.71%
|
$152,280
$8.91 P/Share
|
|
Mar 23
2022
|
Waage Christian EVP, Tech Ops and Admin |
SELL
Open market or private sale
|
Direct |
10,722
-1.82%
|
$85,776
$8.91 P/Share
|
|
Mar 16
2022
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,278
-2.88%
|
$50,224
$8.28 P/Share
|
|
Mar 16
2022
|
Caryn Peterson EVP, Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
6,279
-8.67%
|
$50,232
$8.28 P/Share
|
|
Mar 16
2022
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,002
-5.25%
|
$40,016
$8.28 P/Share
|
|
Oct 25
2021
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,377
-1.08%
|
$28,524
$12.25 P/Share
|
|
Oct 25
2021
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,377
-2.43%
|
$28,524
$12.25 P/Share
|
|
Oct 25
2021
|
Caryn Peterson EVP, Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
2,377
-3.18%
|
$28,524
$12.25 P/Share
|
|
Jun 30
2021
|
Laura Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+20.38%
|
-
|
|
Jun 21
2021
|
Richard Aranda Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+6.39%
|
-
|
|
May 03
2021
|
Laura Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,820
+12.96%
|
-
|
|
Apr 16
2021
|
Caryn Peterson EVP, Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
10,820
+12.63%
|
-
|
|
Mar 23
2021
|
Waage Christian EVP, Tech Ops and Admin |
SELL
Open market or private sale
|
Direct |
5,490
-0.92%
|
$49,410
$9.48 P/Share
|
|
Mar 23
2021
|
Bryan Giraudo COO/CFO |
SELL
Open market or private sale
|
Direct |
5,490
-4.76%
|
$49,410
$9.48 P/Share
|
|
Mar 23
2021
|
Luisa Salter Cid Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,491
-2.6%
|
$49,419
$9.48 P/Share
|